ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Hyperlipidemia and mortality in patients on peritoneal dialysis

Feng, Xiaoran; Zhan, Xiaojiang; Wen, Yueqiang; Peng, FenFen; Wang, Xiaoyang; Wang, Niansong; Wu, Xianfeng*; Wu, Junnan*广州医学院; 南昌大学; 南方医科大学; 上海交通大学; 浙江大学; 郑州大学; 6; 1
BMC Nephrology2022-10-24DOI: 10.1186/s12882-022-02970-w
2被引12阅读
引用收藏
分享

摘要

Background New lipid-lowering therapy at the start of dialysis and measurement of lipid parameters over the follow-up period is not recommended in dialysis patients, which seems unappropriated in clinical practice. We aimed to examine the effect of hyperlipidemia on mortality in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Methods A retrospective cohort study was performed, including 2939 incident CAPD patients from five dialysis facilities between January 1, 2005, and December 31, 2018. The primary outcome was all-cause mortality. The association between hyperlipidemia at the start of CAPD and all-cause mortality was evaluated using Cox proportional hazards regression. Results Of 2939 with a median age of 50.0 (interquartile range, 39.0-61.0), 1697 (57.7%) were men, 533 (18.1%) had hyperlipidemia, 549 (18.7%) had diabetes mellitus, 1915 (65.2%) had hypertension, and 410 (14.0%) had a history of CVD. During the median follow-up period of 35.1 months, 519 (17.7%) died, including 402 (16.7%, 47.4/1000 patient-years) in the non-hyperlipidemia group and 117 (22.0%, 71.1/1000 patient-years) in the hyperlipidemia group. Over the overall follow-up period, patients with hyperlipidemia had an equally high risk of all-cause mortality throughout follow-up as those without hyperlipidemia ([HR] 1.04, 95% confidence interval [CI] 0.83 to 1.31). However, from the 48-month follow-up onwards, hyperlipidemia was associated with a 2.26 (95% CI 1.49 to 3.43)-time higher risk of all-cause mortality than non-hyperlipidemia. Hypertension modified the association between hyperlipidemia and all-cause mortality (P for interaction < 0.001). A significantly increased risk of all-cause mortality was observed among patients with hypertension (HR 2.27, 95%CI 1.44-3.58). Conclusion Among CAPD patients, hyperlipidemia at the beginning of CAPD was associated with a high risk of long-term mortality. Hypertension may mediate the association. Our findings suggested that long-term lipid-lowering treatment should be used in those patients with hyperlipidemia.

学科与关键词

关键词
Peritoneal dialysisMortalityHyperlipidemiaHypertension
相关
加载中…
  • The Association between Baseline Serum Lipids and Mortality in Peritoneal Dialysis Patients
    Xie, Qionghong; Shang, Da; Wang, Yujia; Zhang, Min; Chen, Yun; Xu, Rong; Han, Qingfeng; Ren, Yeping; Chen, Jianghua; Zhao, Huiping; Chen, Menghua; Dong, Jie; Hao, Chuan-Ming; Zhu, Tongying*Blood Purification, 2022, 51(2): 101-110.被引 2
  • Low-Density Lipoprotein Cholesterol and Mortality in Peritoneal Dialysis
    Wu, Xianfeng*; Zhou, Lei; Zhan, Xiaojiang; Wen, Yueqiang; Wang, Xiaoyang; Feng, Xiaoran; Wang, Niansong; Peng, Fenfen; Wu, Junnan*Frontiers in Nutrition, 2022, 9: 910348.被引 2
  • Coexistence of diabetes mellitus and pre-existing cardiovascular disease and mortality in Chinese patients on peritoneal dialysis
    Lei, Guangtao; Feng, Xiaoran; Wang, Xiaoyang; Wen, Yueqiang; Peng, FenFen; Wang, Niansong; Zhan, Xiaojiang; Wu, Qinghua*; Wu, Xianfeng*BMC Nephrology, 2022, 23(1): 68.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
BMC Nephrology
发表日期
2022-10-24
卷期
第 23 卷, 第 1 期
页码
342
DOI
10.1186/s12882-022-02970-w
语言
ENGLISH
期刊等级
4区
成果收录
SCIE

作者

  • F

    Feng, Xiaoran (第一作者)

    1

  • Z

    Zhan, Xiaojiang

    1 · nanchang univ

查看全部 8 位作者收起作者
  • W

    Wen, Yueqiang

    2 · guangzhou med univ

  • P

    Peng, FenFen

    southern med univ

  • W

    Wang, Xiaoyang

    1 · zhengzhou univ

  • W

    Wang, Niansong

    6 · shanghai jiao tong univ

  • W

    Wu, Xianfeng (通讯)

    6 · shanghai jiao tong univ

  • W

    Wu, Junnan (通讯)

    zhejiang univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417